Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: leaptx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/28/2024 | $8.00 | Buy | Rodman & Renshaw |
| 10/4/2021 | $6.00 | Buy | Mizuho |
| 9/14/2021 | $3.00 → $4.00 | Outperform | Raymond James |
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the appointment of Richard L. Schilsky, MD, FASCO, FACP, FSCT to its Board of Directors, effective September 1, 2022. Dr. Schilsky brings over 40 years of experience in medicine and clinical research, specializing in new drug development and clinical trials for a wide range of cancers. "We are honored to welcome Dr. Schilsky, who brings a wealth of experience and deep knowledge to bolster Leap's drug development strategy," said Christopher Mirabelli, PhD, Chairman of Leap Therapeutics' Board. "He is a
Rodman & Renshaw initiated coverage of Leap Therapeutics with a rating of Buy and set a new price target of $8.00
Mizuho initiated coverage of Leap Therapeutics with a rating of Buy and set a new price target of $6.00
Raymond James reiterated coverage of Leap Therapeutics with a rating of Outperform and set a new price target of $4.00 from $3.00 previously
Robert W. Baird resumed coverage of Leap Therapeutics with a rating of Outperform and set a new price target of $5.00
Raymond James initiated coverage of Leap Therapeutics with a rating of Outperform and set a new price target of $3.50
Raymond James reiterated coverage of Leap Therapeutics with a rating of Outperform and set a new price target of $3.50 from $2.50 previously
Raymond James reiterated coverage of Leap Therapeutics with a rating of Outperform and set a new price target of $3.50 from $2.50 previously
CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024. Leap Highlights: Completed enrollment in the expanded randomized controlled Part B of the Phase 2 DeFianCe study evaluating DKN-01, Leap's anti-DKK1 monoclonal antibody, in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC); data expected in mid-2025Patient follow-up continuing in the randomized controlled Part C of the Phase 2 DisTinGuish study evaluating DKN-01 in
CAMBRIDGE, Mass., Sept. 30, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment of 188 patients has been completed in the randomized controlled Part B of the DeFianCe study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanced colorectal cancer (CRC). "The completion of enrollment in Part B of the DeFianCe study marks a significant achievement and highlights the enthusiasm in the potential of DKN-01 from both patients and healthcare providers
CAMBRIDGE, Mass., Aug. 12, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2024. Leap Highlights: Overall response rate (ORR) increases to 33% across all evaluable patients and 38% across evaluable patients with left-sided CRC in updated data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC)Expanded the randomized controlled Part B of the DeFianCe study to 180 patients; enrollment expected to be comple
CAMBRIDGE, Mass., May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024. Leap Highlights: Completed $40 million private placement financing with participation from Gilead Sciences, Inc., a life sciences-focused investor, Samsara BioCapital, 683 Capital Partners, LP, Laurion Capital Management, and Rock Springs CapitalPresented clinical data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal ca
Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development program CAMBRIDGE, Mass., April 11, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock ("Common Stock") at a price of $2.82 per share and pre-funded warrants to purchase 1,523,404 shares of Common Stock at a pric
CAMBRIDGE, Mass., March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2023. Leap Highlights: Presented new clinical data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer, at the 2024 ASCO Gastrointestinal Cancers SymposiumCompleted enrollment in the randomized controlled Part C of the Phase 2 DisTinGuish study evaluating DKN-01 in combination with tislelizumab and chemothe
30% ORR and 93% DCR across heterogenous second-line CRC patientstreated with DKN-01 plus bevacizumab and chemotherapy Subgroup analysis reveals greatest benefit in left-sided tumors, particularly rectal and rectosigmoid patients with 46% ORR, 100% DCR, and preliminary median PFS of 9.4 months. Leap to host conference call to report additional clinical data including further subgroup analyseson Tuesday, January 23, 2024 at 8:30 a.m. ET CAMBRIDGE, Mass., Jan. 16, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced new data from Part A of the DeFianCe study, a Phase 2 study evaluatin
CAMBRIDGE, Mass., Jan. 3, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Leap Presentation Details: 42nd Annual J.P. Morgan Healthcare ConferenceDate: Wednesday, January 10, 2024Time: 1:30 p.m. Pacific Time A live webcast of the presentation may be accessed on the Investors page of the company's website at https://investors.leaptx.com/, where a replay of the events will also be available for a limited time. A
CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in the randomized controlled Part C of the DisTinGuish study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy in patients with advanced gastroesophageal junction and gastric cancer. "The completion of enrollment in Part C of the DisTinGuish study is an important milestone and continues to underscore the high level of interest from both patients and investigators in DKN-01," said
CAMBRIDGE, Mass., Dec. 11, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new data in second-line patients with advanced colorectal cancer from the DeFianCe study, a Phase 2 study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy at the upcoming 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium taking place in San Francisco, CA and virtually on January 18-20, 2024. Leap Presentation Details: Title: DKN-01 plus bevacizumab and chemot
SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G/A - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
10-Q - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
S-8 - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
10-Q - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
EFFECT - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
424B3 - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
DEFA14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
Rodman & Renshaw analyst Tony Butler initiates coverage on Leap Therapeutics (NASDAQ:LPTX) with a Buy rating and announces Price Target of $8.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Leap Therapeutics (NASDAQ:LPTX) with a Buy and lowers the price target from $7 to $5.5.
- SEC Filing
Gainers XTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 13.9% to $2.71 during Wednesday's after-market session. The market value of their outstanding shares is at $14.7 million. Leap Therapeutics (NASDAQ:LPTX) shares rose 11.21% to $2.84. The market value of their outstanding shares is at $72.6 million. As per the press release, Q4 earnings came out 2 days ago. Jaguar Health (NASDAQ:JAGX) stock rose 10.94% to $0.09. The company's market cap stands at $18.2 million. Sharps Technology (NASDAQ:STSS) shares moved upwards by 9.73% to $0.37. The market value of their outstanding shares is at $5.6 million. Universe Pharmaceuticals (NASDAQ:UPC) shares rose 8.88% to $1.96. The compa
Baird analyst Joel Beatty maintains Leap Therapeutics (NASDAQ:LPTX) with a Outperform and lowers the price target from $11 to $9.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Leap Therapeutics (NASDAQ:LPTX) with a Buy and maintains $7 price target.
CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024. Leap Highlights: Completed enrollment in the expanded randomized controlled Part B of the Phase 2 DeFianCe study evaluating DKN-01, Leap's anti-DKK1 monoclonal antibody, in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC); data expected in mid-2025Patient follow-up continuing in the randomized controlled Part C of the Phase 2 DisTinGuish study evaluating DKN-01 in
CAMBRIDGE, Mass., Aug. 12, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2024. Leap Highlights: Overall response rate (ORR) increases to 33% across all evaluable patients and 38% across evaluable patients with left-sided CRC in updated data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC)Expanded the randomized controlled Part B of the DeFianCe study to 180 patients; enrollment expected to be comple
CAMBRIDGE, Mass., May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024. Leap Highlights: Completed $40 million private placement financing with participation from Gilead Sciences, Inc., a life sciences-focused investor, Samsara BioCapital, 683 Capital Partners, LP, Laurion Capital Management, and Rock Springs CapitalPresented clinical data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal ca
CAMBRIDGE, Mass., March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2023. Leap Highlights: Presented new clinical data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer, at the 2024 ASCO Gastrointestinal Cancers SymposiumCompleted enrollment in the randomized controlled Part C of the Phase 2 DisTinGuish study evaluating DKN-01 in combination with tislelizumab and chemothe
30% ORR and 93% DCR across heterogenous second-line CRC patientstreated with DKN-01 plus bevacizumab and chemotherapy Subgroup analysis reveals greatest benefit in left-sided tumors, particularly rectal and rectosigmoid patients with 46% ORR, 100% DCR, and preliminary median PFS of 9.4 months. Leap to host conference call to report additional clinical data including further subgroup analyseson Tuesday, January 23, 2024 at 8:30 a.m. ET CAMBRIDGE, Mass., Jan. 16, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced new data from Part A of the DeFianCe study, a Phase 2 study evaluatin
CAMBRIDGE, Mass., March 24, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2022. Leap Highlights: Acquired Flame Biosciences, adding FL-301, a clinical stage anti-Claudin18.2 antibody, and preclinical antibody programs targeting Claudin18.2/CD137 and GDF15 to Leap's pipelinePresented clinical data from Part B of the Phase 2 DisTinGuish study of DKN-01 plus tislelizumab in gastroesophageal (GEA) cancer patients whose tumors express high levels of DKK1 (DKK1-high) and preclinical data supporting the activity o
Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap's pipeline Combined cash balance of approximately $115 million enhances runway to mid-2025, fully-funding advancement of DKN-01 and FL-301 Leap to host conference call at 9:00 a.m. ET today CAMBRIDGE, Mass., Jan. 17, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and Flame Biosciences, Inc., a privately-held biotechnology company, today announced that the companies have entered into a definitive merger agreement pursuant to which Leap has acquired Flame and its assets, including FL-301, its c
CAMBRIDGE, Mass., Jan. 18, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium being held on January 20-22, 2022. The Company will host a conference call with Dr. Samuel Klempner of Harvard Medical Schoo
CAMBRIDGE, Mass., Sept. 16, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the presentation of updated positive data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.'s anti-PD-1 antibody, and chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the European Society for Medical Oncology (ESMO) Congress. The Company will host a conference call on Friday, September 17, 2021 to discuss preliminary results from t
CAMBRIDGE, Mass., Sept. 13, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting initial data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.'s anti-PD-1 antibody, and chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the European Society for Medical Oncology (ESMO) Congress, being held virtually on September 16-21, 2021. The Company will host a conference call on Friday, Septembe